XiaoMi-AI文件搜索系统
World File Search SystemAnnounced
4月8日星期一新闻稿
Lausanne, Switzerland – April 4 th , 2024 – Debiopharm ( www.debiopharm.com ), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standard-of-care to cure cancer and infectious diseases, today announced preclinical data releases for two of their compounds inhibiting the DNA-damage response (DDR) of cancer cells, including Debio 0123 [选择性WEE1抑制剂]和Debio 0432 [选择性USP1抑制剂]在加利福尼亚州圣地亚哥举行的2024年度美国癌症研究协会（AACR）峰会上。
松下能量和马自达开始准备...
Osaka and Hiroshima, Japan , September 6, 2024 – Panasonic Energy Co., Ltd. (“Panasonic Energy”), a Panasonic Group Company and Mazda Motor Corporation (“Mazda”) today announced that they will prepare for the supply of next-generation cylindrical automotive lithium- ion batteries, in anticipation of their installation in Mazda's battery electric vehicles （BEV）计划从2027年开始引入。这是在他们以前达成的协议之后，反映了他们建立中长期伙伴关系的目的。日本经济，贸易和行业部在同一天批准其与电池生产和技术开发扩展的联合项目，这是其建立稳定电池供应的计划的一部分。
Wilson-Sonsini-Advises-GC-Therapeutics-On- 6500万美元...
On September 19, 2024, GC Therapeutics (GCTx), a biopharmaceutical company created to scale and unlock the next generation of cell therapy-based medicines, launched and announced the successful completion of a $65 million Series A financing led by Cormorant Asset Management with participation from Mubadala Capital, Andreessen Horowitz (a16z) Bio + Health, Medical Excellence Capital, Cercano Management, and Pear VC，将GCTX筹集的总资本提高到7500万美元。Wilson Sonsini Goodrich＆Rosati就交易建议GC Therapeutics。Wilson Sonsini Goodrich＆Rosati就交易建议GC Therapeutics。
口服半卢比25 mg和50毫克的HBA 1C和体重的降低与先锋> 2型糖尿病患者相比14毫克
Bagsværd, Denmark, 24 March 2023 – Novo Nordisk today announced headline results from the PIONEER PLUS trial, a phase 3b, 68-week, efficacy and safety trial with once-daily oral semaglutide 25 mg and 50 mg versus 14 mg as add-on to a stable dose of 1–3 oral antidiabetic medicines in people with type 2 diabetes in need of treatment intensification.该试验通过在第52周证明HBA 1C的统计学意义和出色的降低来实现其主要终点，而25 mg和50 mg剂量与14 mg口服semaglutide相比。
在国家电信和信息管理局之前
4 NGA研究优先级，可在https://nextgalliance.org/research-priorities/上获得。5 The Joint Statement from India and the U.S., announced that ”[s]haring a vision of secure and trusted telecommunications, resilient supply chains, and global digital inclusion, Prime Minister Modi and President Biden welcomed the signing of a Memorandum of Understanding (MoU) between Bharat 6G Alliance and Next G Alliance, operated by Alliance for Telecommunications Industry Solutions, as a first step towards deepening public- private供应商与运营商之间的合作。” https://www.whitehouse.gov/briefing-room/Statement-版本/2023/09/08/toction-statement-from-india-india-india-ind-the-the-the-in-United-States/
Transgene和NEC在ACR 2024
Strasbourg，法国和日本东京，2024年4月9日，下午5:45 CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies, announced that new data will be presented on TG4050, an individualized neoantigen cancer vaccine, at the American Association for Cancer Research (AACR) Annual Meeting in San迭戈，加利福尼亚 这些数据在今天举行的AACR新闻发布会上以及将于4月10日上午9:00在PDT举行的海报演示中强调。 TG4050基于Transgene的MyVac®平台，并由NEC的尖端AI功能提供动力，旨在优化抗原选择。 海报的关键发现包括：Strasbourg，法国和日本东京，2024年4月9日，下午5:45 CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies, announced that new data will be presented on TG4050, an individualized neoantigen cancer vaccine, at the American Association for Cancer Research (AACR) Annual Meeting in San迭戈，加利福尼亚这些数据在今天举行的AACR新闻发布会上以及将于4月10日上午9:00在PDT举行的海报演示中强调。TG4050基于Transgene的MyVac®平台，并由NEC的尖端AI功能提供动力，旨在优化抗原选择。海报的关键发现包括：
TEPCO生物多样性报告2024
TNFD代表与自然有关的财务披露工作组。这个由私营部门领导的工作组敦促公司披露其与自然环境和生物多样性有关的风险和机会，以便金融机构和投资者可以做出适当的投资决策。In addition to the recommended disclosures structured around the four recommendation pillars (governance, strategy, risk and impact management, metrics and targets) and metrics, the final recommendations announced by the TNFD in September 2023 include the LEAP approach, which provides guidance on the integrated approach for the identification and assessment of nature- related issues, and also multiple frameworks that consist of sector and biome- based guidance, and individual guidance for scenario analysis and target 环境。
建立“智能移动技术（C-V2X）联盟”
ASTRI announced the establishment of the “Smart Mobility Technology (C-V2X) Alliance” (SMTA), to enhance the Smart Mobility ecosystem in Hong Kong, fostering more collaboration amongst industry, academia and research on Smart Mobility and related technologies, and facilitating Hong Kong in the deployment of C-V2X technology and infrastructure, that will help Hong Kong to become an exemplar of聪明的城市。运输和物流部长Lam Sai-Hung先生以及来自学术和智能流动性部门的专家和行业领导者聚在一起见证了SMTA的建立。“数字经济峰会 - 智能移动论坛”也被认为分享了技术及其未来发展的最初成就，并讨论了香港及其解决方案中C-V2X应用程序的挑战，以及在自动驾驶中商业化等问题。
Cabinet Secretary for Net Zero and Energy
Dear Edward, Thank you for the opportunity to appear before the Net Zero, Energy and Transport Committee to discuss the programme of work that the Scottish Government is undertaking on climate change. You asked to be provided with some information in advance of this to support the Committee's preparation for that session - please find my response to that request below which I hope the Committee will find useful. Climate Change Plan and proposed Climate Change Bill As I announced on 18 April, development of the next Climate Change Plan is now continuing in the context of forthcoming proposals for legislative change. My immediate priority is to address the points raised by the CCC in their latest progress report and introduce legislation to Parliament in due course. It is important to underline that this Government remains fully committed to meeting our target of net zero emissions by 2045 at the latest. With emissions already cut by almost 50%, we are now entering the second half of our journey to net zero. While we are seeking to realign our target pathway to Climate Change Committee advice, I must be clear that there is no change in the challenge ahead: we have twenty years to finish the job and reach net zero. The hardest part of this journey is undoubtedly ahead of us and all parties must be prepared to join us in making the difficult delivery decisions that will be required to deliver our shared aim. This means we must continue driving down emissions as fast as we can, in a way that is just and fair. That is why this Government announced earlier this month a raft of new climate action in transport, agriculture, taxation, land use and industry. In this next phase of our journey these announcements will set the context for the next Climate Change Plan. The full package of new climate action can be found here but includes, for example:
峰会治疗学将在第43届年度J.P. ...
Summit Therapeutics to Present at the 43 rd Annual J.P. Morgan Healthcare Conference Miami, Florida, January 7, 2025 – Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 13，2025在下午3:00。Robert W. Duggan，董事长兼首席执行官，首席执行官兼总裁Maky Zanganeh博士将介绍公司概述和有关我们组织进度的最新信息，包括开发我们创新的双特异性抗体Ivonescimab。演示文稿将从我们的网站：www.smmttx.com现场直播。演示文稿后，将在我们的网站上找到演示文稿的存档版本。